Lifetech LAmbre™ Left Atrial Appendage Closure System Post-Market Registry

Atrial Fibrillation Clinical Trial

Official title:

Lifetech LAmbre™ Left Atrial Appendage Closure System Post-Market Registry Single-center, Single-arm, Prospective, Post-market Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04307927
• Other study ID #: LA-PMCF-02
• Status: Recruiting
• Start date: March 14, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2022
• Source: Lifetech Scientific (Shenzhen) Co., Ltd.
• Contact: Yun Li
• Phone: +86 13534247025
• Email: liyun[@]lifetechmed.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Single-center, single-arm, prospective, post-market study of LAmbre™ LAA Closure System. To evaluate immediate and long term procedural success of Lifetech LAmbre™ occluders in patients.

Description:

Detailed Description:

Atrial fibrillation (AF) is the most common cardiac arrhythmia causing ischemic stroke. The CHA2DS2-VASc score was developed to estimate the stroke rate in patients with non-valvular AF, and high scores predict a raised annual stroke risk. The yearly stroke risks without treatment in patients with CHA2DS2-VASc score 2 and 9 are 2.2% and 15.2% respectively. For patients with increased stroke risk (CHA2DS2-VASc score ≧2), warfarin or other novel oral anticoagulants (NOAC) recommended for stroke prevention. Despite the effectiveness of current pharmacological therapies for stroke prevention in atrial fibrillation, around 20% of patients discontinue therapy - whether new oral anticoagulants (NOAC) or warfarin because of side effects and/or bleeding. In addition, warfarin needs to be dosed individually to target an international normalized ratio (INR) of 2-3 for striking an optimal balance between bleeding and ischemic stroke events. This, combined with drug-drug interaction that occurs with both NOACs and warfarin, results in inadequate stroke protection in a substantial portion of AF patients. The LAA is the source of 90% of cardiac emboli attributed to stroke events. This is a windsock-like structure on the lateral border of the left atrium with internal trabeculations, and being a confined space, is prone to blood stasis and thrombus formation. Currently, there are surgical, epicardial and percutaneous techniques for occluding this structure in order to reduce stroke in AF patients cannot take long term oral anticoagulants, and the percutaneous route is intuitively the most attractive given its relative non-invasiveness. The two devices in most widespread use for percutaneous LAA closure worldwide are the Watchman (Boston Scientific, Natick, MA, USA) and the Amplatzer Cardiac Plug (ACP) (Abbott, IL, CA USA). However, both devices have limitations including the need for relatively large delivery sheaths (9-14 French) and limited recapture and repositioning capabilities.

LAmbreTM LAA Closure System (Lifetech Scientific, Shenzhen, China) is a novel self-expanding LAA occluder constructed from a nitinol mesh and polyester membranes and consists of an umbrella and a cover connected by a short central waist. The device is delivered by an 8-10 French sheath and has full recapture and repositioning capabilities. LAmbreTM LAA Closure System received the CE mark in June 2016.

This PMCF study will be carried out following the CE mark of LAmbreTM LAA Closure System and is intended to confirm the effectiveness and safety of LAmbreTM LAA Closure System.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Patients must be at least 18 years of age; 2. Patients with non-valvular paroxysmal, persistent or permanent atrial fibrillation with long-term sustainability scheduled for interventional LAA closure; 3. Patient characteristics consistent with the corresponding IFU and sizing guidelines*; 4. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Ethics Committee (EC); 5. The patient agrees to comply with requirements of the study including the 24 months follow- up.

Exclusion Criteria:

• 1. Any contra-indication mentioned in the corresponding IFU*; 2. Currently participating in other investigational drug- or device studies; 3. Patient who is pregnant, planning to become pregnant, or breast feeding; 4. Patients cannot tolerate transoesophageal echocardiogram (TEE).

• Note: In IFU, the Left Atrial Appendage Closure System is contraindicated for the following: • Patients' LAA anatomy not suitable for the REF of the device.

• Patients' with intracardiac thrombus.

• Patients with active endocarditis or other infections causing bacteremia.

• Patients where placement of the device would interfere with any intracardiac or intravascular structures.

• Patients with contraindications to X-Ray and/or trans-esophageal echocardiographic examinations.

• Patients with known hypersensitivity to nickel.

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
Germany	Katholisches Klinikum Koblenz ·Montabaur	Koblenz

Sponsors (1)

Lead Sponsor	Collaborator
Lifetech Scientific (Shenzhen) Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1.Absence of peri-procedural stroke/TIA, device embolization, cardiac or vascular perforation, any other device or procedure related serious adverse event or death (procedure or device related or of unknown cause);	Peri-procedure defined as within 7 days of the procedure.	7 days
Primary	Implant success	Implant success defined as correct positioning and release of the occluder device into the proper anatomical location. Correct positioning is assessed as absence of major residual jet flow (>5mm) into the LAA closure with the device evaluated by transesophageal echocardiogram (TEE).	1 day
Secondary	Incidence of stroke or systemic embolism or death through 24 months post implantation	Incidence of stroke or systemic embolism or death through 24 months post	24 months
Secondary	Successful sealing around the device at the LAA orifice with residual jet =5 mm flow measured by TEE at 1-3 months, 6 months post-implantation	Successful sealing around the device at the LAA orifice with residual jet =5 mm flow measured by TEE at 1-3 months, 6 months post-implantation	1-3 months, 6 months post-implantation
Secondary	Device or procedure related Serious Adverse Events (SAEs) from attempted procedure through 24 months post implantation	Device or procedure related Serious Adverse Events (SAEs) from attempted procedure through 24 months post implantation	24 months
Secondary	All SAEs (death included) from attempted procedure through 24 months post implantation	All SAEs (death included) from attempted procedure through 24 months post implantation	24 months
Secondary	Incidence of bleeding event through 24 months post implantation.	Incidence of bleeding event through 24 months post implantation.	24 months